Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
Strategic Plan
pCPA Revitalization
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Dupixent (dupilumab)
pCPA File Number:
22214
Negotiation Status:
Under consideration for negotiation
Indication(s):
atopic dermatitis
Sponsor/Manufacturer:
Sanofi Genzyme Canada
CADTH Project Number:
SF0754
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable